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Non-invasive detection of urinary
bladder cancer remains a significant
challenge. Urinary volatile organic
compounds (VOCs) are a promising
alternative to cell-based biomarkers.
Herein, we demonstrate a novel diag-
nosis system based on an optic fluores-
cence sensor array for detecting
urinary bladder cancer VOCs bio-
markers. This study describes a
fluorescence-based VOCs sensor array
detecting system in detail. The choice
of VOCs for the initial part was based on an extensive systematic search of the lit-
erature and then followed up using urinary samples from patients with urinary
bladder transitional cell carcinoma. Canonical discriminant analysis and partial
least squares discriminant analysis (PLS-DA) were employed and correctly
detected 31/48 urinary bladder cancer VOC biomarkers and achieved an overall
77.75% sensitivity and 93.25% specificity by PLS-DA modelling. All five urine
samples from bladder cancer patients, and five healthy controls were successfully
identified with the same sensor arrays. Overall, the experiments in this study
describe a real-time platform for non-invasive bladder cancer diagnosis using
fluorescence-based gas-sensor arrays. Pure VOCs and urine samples from the
patients proved such a system to be promising; however, further research is
required using a larger population sample.
KEYWORDS
bladder cancer, fluorescence gas-sensory arrays, urinary volatile organic
compounds
1 | INTRODUCTION
Non-invasive detection of urinary bladder cancer remains the
focus of ongoing research in urologic oncology. Besides early
detection, urinary-based biomarkers have huge potential in
predicting recurrence of non-muscle invasive disease which
incur a high cost to healthcare organisations during invasive
follow-up cystoscopy management [1]. Cystoscopy-aided
biopsy and histopathological confirmation remain the gold-
standard against which several biomarkers have been tested in
the past [2]. Disease-specific volatile organic compounds
(VOCs) in the form of cancer biomarkers provide a new
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exciting perspective for early cancer detection in urinary blad-
der and other site cancers [3, 4].
VOCs are organic chemicals (eg, alcohols, alkanes, aro-
matics) that have vapour pressure greater than 100 Pa at
ambient temperature. They are commonly released from the
human body in exhaled breath and are present in blood, skin,
saliva, faeces and urine [5]. They are produced through cel-
lular activities entering the blood stream and contain a
wealth of information about cellular behaviour and their
metabolic changes. Such cellular activity products are then
concentrated through kidney and finally excreted through
urine [6]. Different VOCs are produced both by cancerous
and healthy cells during various metabolic and nutritional
activities [4, 7, 8]. However, certain VOCs are not produced
during normal physiological processes, but their production
is related to pathological conditions. Correlation with the
presence of cancer is plausible as a number of VOCs are
exclusively produced during carcinogenesis and become
candidate biomarkers for cancer detection [9]. The emission
of VOCs by cancerous cells could be the result of peroxida-
tion of the cell membrane species owing to genetic-changes
causing oxidative stress [10–12].
The discernment of VOCs in exhaled breath as an early-
stage lung cancer diagnostic and for monitoring the response
to treatment in advance lung cancer has already been
reported [13, 14]. Similarly and in parallel, diagnosis of
bladder and prostate cancer based on the sense of smell of
trained dogs is also based on the presence of specific VOCs
in the urine of patients with the disease has been
observed [15–17].
The most common techniques utilised for the detection
of VOCs in urinary bladder cancer are gas chromatography-
mass spectrometry (GC-MS [18]), selected ion flow tube-
mass spectrometry (SIFT-MS [19]) and gas responsive
sensors (e-noses [20]). The high reliability in identification
of analytes and robust sensitivity (less than parts-per-billion
[ppb] to parts-per-trillion [ppt] [21, 22]) makes GC-MS the
most commonly used analytical technique. Jobu et al.
applied GC-MS analysis to urine samples from bladder can-
cer patients and healthy controls, finding found five charac-
teristic peaks within GC-MS signals of bladder cancer
patients not present in healthy controls. They suggested that
those peaks were because of ethylbenzene, nonanoyl chlo-
ride, dodecanal, (Z)-2-nonenal and 5-dimethyl-3(2H)-isoxa-
zolone, and these can be used as biomarkers for urinary
bladder cancer [18].
A disadvantage of GC-MS is that it cannot be used in
real time. On the other hand, proton-transfer-reaction mass
spectrometry, which has a higher sensitivity than GC-MS
(low ppb-low ppt [23, 24]), can be employed in real time;
however, this does not discriminate between compounds
with the same molecular weight. SIFT-MS allows the detec-
tion in real time, is quite sensitive (sub-ppb to low ppb [25])
and is reliable in identification of VOCs. A study involving
the use of SIFT-MS proved that patients with bladder cancer
have a significantly higher concentration of formaldehyde in
their urine headspace than health controls [19].
In recent years, attention has moved towards deploying e-
noses for the detection of VOCs in different cancers, but there
are only a limited number of reports regarding diagnosis of uri-
nary bladder cancer [4, 26, 27]. e-nose technology is based on
chemical sensors array and pattern recognition through sensor-
specific responses to VOC molecules. The technique can
detect and analyse VOCs with a sensitivity of low ppb [28].
Different types of detection methods have been developed for
e-nose sensors, such as metal-oxide semiconductors sensors,
conducting polymer sensors, piezoelectric sensors, optical sen-
sors, surface acoustic wave sensors, and quartz microbalance
(QMB) sensors [29]. They are particularly appealing, because
they can be miniaturised and are much cheaper and less time-
consuming than mass spectrometry techniques [30]. Among
the different sensing technologies, optical gas sensors based
on optically active organic materials, such as porphyrins and
metalloporphyrins, have been successfully employed to
develop an e-nose prototype for the detection and quantifica-
tion of VOCs in exhaled breath [7]. Gasparri et al. recently
reported employing porphyrin-coated QMB sensor array e-
nose to diagnosis lung cancer in 146 breath samples from
70 lung cancer patients and 76 healthy controls reaching
81% sensitivity and 91% specificity [13]. A recent study
involved 60 urine samples from 30 bladder cancer patients
and 30 healthy controls using commercially available e-nose
Cyranose 320 (Sensigent, Baldwin Park, California) and
achieved 93.3% sensitivity and 86.7% specificity; however,
the sample size of this study was relatively small, and it
lacked external validation in its prediction model [31].
In the present study, we propose that changes in fluores-
cence properties of sensitive materials such as porphyrins
and metalloporphyrins when exposed to urinary VOCs could
provide essential information for the detection of urinary
bladder cancer. Based on our previous experience, we
believed that change in fluorescence constituted an impor-
tant diagnostic marker of bladder cancer [32, 33].
The optical sensitivities of porphyrins and metalloporphyrins
to VOCs are bases on π-π interactions and the n-π interactions
that reflect changes in porphyrins' absorption, fluorescence and
reflectance spectrums. Before the reaction with VOCs, the
energy difference between the highest occupied molecular
orbital and the lowest unoccupied molecular orbital (HOMO-
LUMO gap) determines the absorbance peak. The interactions
between porphyrins and VOCs lead to a change of the electron
dipole moment, causing a change in the energy gap between the
two orbitals, therefore resulting in a change of the absorbance
and fluorescence emission spectrums of porphyrins.
With the background, we sought to construct an optical
sensory-based method for the detection of bladder cancer
with significant potential of miniaturisation and point-of-
care test.
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2 | MATERIALS AND METHODS
Based on extensive literature research [18, 34, 35], four
bladder cancer urinary biomarker VOCs were chosen in this
study: ethylbenzene, hexanal, laurie aldehyde and nonanoyl
chloride, and all chemicals were purchased from Sigma-
Aldrich and used without further purification.
2.1 | Manufacture of fluorescence gas-sensor arrays
The 8-element sensor arrays were developed by spotting the
sensitive materials on polyvinylidene fluoride (PVDF) film.
The sensitive materials contained three porphyrins, two fluo-
rescence dyes, two solvatochromic dyes and one pH indica-
tor [7, 36–38]. All sensitive materials were prepared to 5%
tetrahydrofuran solution and each spotting point featured
1.5 μL of the solution (75 ng solute). For the single chamber
test, the sensor array films were cut into small pieces featur-
ing one sensory point on each piece to fit it within the single
chamber. For the multi-element test, all eight sensitive mate-
rials were spotted on one film, and the arrangement of each
points was precisely controlled to permit the excitation laser
beam to focus on the exact position of each sensory point.
2.2 | Single-element chamber test: Proof-of-concept
To validate the performance of the sensitive material, the
single-element reaction chamber was made and tested with
saturated bladder cancer-specific biomarker VOCs vapours.
The three-dimensional (3D) printed reaction chamber
(Figure 1) has two parts: the upper part has a hole to let the
detection probe of the LAKK-M laser device to fit in, and
the lower part has a stand to support the sensor film and be
able to allow the VOCs vapours spread into the chamber.
The two parts were screwed together to ensure a tightly
sealed environment. First, the reaction chamber with a
single-element sensor film was mounted on the empty flask,
and the fluorescence spectrum under ultraviolet (UV;
365 nm), blue (450 nm), and green (532 nm) excitation light
was detected by the LAKK-M device. An accumulation of
15 spectra was recorded using an acquisition time of 150 ms
per exposure at an excitation power of 4.2 mW. Second,
5 mL of VOC liquid was added into a flask and warmed to
37C, and the VOC gas was released and spread into the
chamber to be reacted with the sensitive materials on the
sensor film. After 2 minutes wait for the reaction to take
place, the fluorescence spectra for the same excitation lights
were recorded. Through the single-element test chamber, the
distance between the light fibre tips to the film was fixed at
6 mm, permitting the light source to illuminate a 4-mm
diameter circle area. After repeatedly experiments, current
distance and illuminate area were determined. Fluorescence
intensity of the sensitive materials can be maintained for 30s
under exposure of UV light and 1 minute under blue light.
The films were discarded after each test.
To reduce errors, the background signal of the device
was measured, and the data showed that the materials of the
3D print device and substrate can cause background fluores-
cence. The main reason is that the polymer materials will
emit fluorescence, especially under UV and blue light excita-
tion. Finally, we chose black PVA (Polyvinyl alcohol) as 3D
FIGURE 1 Sketch and work flow of the system and the 3D sketch of single-element reaction chamber. The multi-element chamber using the same gas
delivery and optic system with an extra mechanical device for switching the sensory elements. MCU, Multipoint Control Unit
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printing material and low-fluorescence PVDF as a substrate.
The background of the substrates and chamber material was
measured before each test as the reference.
2.3 | Multi-elements array tests: Automatic real-time
system
The experimental design and system workflow are portrayed
in Figure 1. The system has two parts: a control unit and pro-
cess unit. The control unit has a host computer connected
with multiple input and output devices—the gas generation
unit controller that controls and records the temperature as
well as flow speed of the liquid sample and carrier gas; an
Arduino Uno (Arduino, Turin, Italy) microcontroller unit
that controls and receives data from the mechanic parts and
environmental sensors (temperature, pressure and humidity)
built-in reaction chamber; fluoresce spectrometer and its
light source (LAKK-M, LAZMA, Moscow, Russia) for fluo-
rescence excitation and receiving. The process unit functions
according to the following steps: the liquid samples and car-
rier gas flows into the vaporisation mixer, the flow speed is
regulated by the corresponding liquid flowmeter and gas
flowmeter. The mixture gas is then passed through the reac-
tion chamber and reacted with the sensitive materials on the
film plate for 2 min. After the reaction, the valve is opened,
and the gas is released to the waste cylinder.
The reaction chamber was re-designed to allow multiple
elements to be exposed and measured together. At each end
of the reaction chamber, a pre-mixture chamber was attached
to the main chamber, the pre-mixture chamber has many
small diversion channels built-in that allows the VOC
vapour mixture to distribute within the chamber evenly. The
sensory array utilised in this system was based on a 5 × 5
layout, which means each film has three 8-element arrays
and one blank reference point.
2.4 | Patient recruitment
Five patients with cystoscopically confirmed bladder cancer
were recruited from the endoscopy unit at Ninewells Hospi-
tal, Dundee, on the day of scheduled treatment. Five age and
gender matched controls with other urological diseases were
recruited from the Urology Outpatient Department from the
same hospital as well. All the participants were free from
urinary tract infections as assessed by dipstick testing prior
to sample collection. All participants first void morning
urine was collected and stored in a sterilised urine beaker for
freezing within 1 hour of collection in a − 20C freezer.
Ethic approval for this study was obtained through the
East of Scotland Research Ethics Service (REC:
17/ES/0003). All participants were given an information
sheet regarding this study, and written consent was obtained
on the day of recruitment. The demographic details of the
participants are presented in Table 1. As a proof-of-principle
study, we sought to test our device on patient samples. The
study is ongoing, and the results from a larger cohort will be
reported subsequently.
2.5 | Urine test
The system for the urine test was modified based on the
multi-element array system mentioned earlier, the gas gener-
ation unit was replaced by a diaphragm pump (RS-Compo-
nents, Corby, UK) controlled by an Arduino
microcontroller, and another setup including the reaction
chamber, sensory film, and ambient sensors was kept the
same as described previously.
Before starting the experiments, the frozen urine was
thawed and pre-warmed to 37C in a water bath and trans-
ferred to 15-mL flasks connected to the reaction chamber by
close-loop recycling tubing. During the first step, the “before”
spectrum was measured without exposure to the vapours of
urine. Then, the diaphragm pump was switched on and it
began pumping the air into the urine, and VOC molecules
were released into the headspace through the bubbling pro-
cess. During the whole test, the pump was cycling the air
within the system and helping shorten the time required for
VOC vapour to reach the gas-liquid phase dynamic balance.
After 5 minute, the “after” spectrum of the sensory film was
evaluated and the whole system was purged with clean air.
2.6 | Software and analysis methods
2.6.1 | Differential spectrum and signal processing
The responses of the sensory point to the presence of VOCs
are based on differential spectrums. It was calculated by sub-
traction of final spectrums with the initial spectrums of each
sensory points. In general, the data file contained 2100 pairs
of data, and each pair had a wavelength reading and corre-
sponding intensity reading.
First, the differential spectrums were normalised with the






where λ is the wavelength, λ1 and λ2 are the two wavelength
boundaries of the observing spectrum and Iλ and I 0λ are the
corresponding original intensity and normalised intensity on
wavelength λ. The normalisation process can reduce the
effect of output power fluctuation of the excitation light, thus
improving reproducibility. Second, the normalised spec-
trums were applied with a de-noising filter to remove the
TABLE 1 Participant demographic of urine test
Bladder cancer Control
Number of individuals 5 5
Mean age (years] 61.8 60.8
Age range (years) 33-79 32-70
Gender (Male: female) 4:1 4:1
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background noise. Savitzky-Golay filtering [39] has been
widely applied in signal processing for de-noising, and it can
remove high-frequency noise efficiently without shift the
fluorescence peaks, which is important for this study.
Finally, the backscattering of the excitation light was
removed from the spectrum and only remained the
emissions.
2.6.2 | Signal characteristic extraction
For each differential spectrum, five spectrum characteristics
were extracted: maximum peak value and wavelength, mini-
mum peak value and wavelength and peak area, as shown in
Figure 2 [7]. MATLAB 2016b (MathWorks, Natick, Massa-
chusetts) was used for both spectrum characteristics extrac-
tion and smoothing process. To evaluate the responses of the
sensitive materials to the VOCs, Canonical discriminant
analysis (CDA) was calculated using SPSS Statistics v22
(IBM, Chicago, Illinois). Compared to principal component
analysis (PCA), the CDA is concentrated on distinguishing
the differences between samples and was more suitable for
evaluating the performance of the sensor arrays. To build the
prediction model, partial least squares discriminant analysis
(PLS-DA [40]) was used for this purpose with MATLAB
2016b, while leave-one-out cross-validation and individual
external validation were applied to evaluate the performance
of the prediction model.
3 | RESULTS AND DISCUSSION
3.1 | Sensory point and film
All the porphyrins family sensitivity materials used in this
study share similar main structure namely tetraphenyl por-
phyrin (TPP), but the different central metal ions and the
substituents on the peripheral benzene rings determined their
different visual colours, as well as fluorescence spectra. The
differences of the central metal ions also reflected in their
responses to the VOCs, and, in general, the fluorescence
spectra exhibited a fluorescence peak red-shift, while on vis-
ible zones the colour changes could be of a shorter wave-
length. Apart from TPP and their derivatives, other
fluorescence dyes were also employed in this study, includ-
ing pH indicators and solvatochromic dyes.
Comparing to commercially widely used e-nose based
on MOS or polymer sensors, the optical VOC sensor array
are relative newer and only few clinical studies being carried
out. Compared to purpose-built polymer sensors, the long-
term costs of the optical sensory film are extremely low, and
such films are easy to upgrade and expand to suit different
applications without changing the design of the main device.
The optical changes are also very intuitional and easy to
accept by clinical staff because it can be very similar to clini-
cally widely used urine dipstick tests.
FIGURE 2 Example of differential spectrum calculated from the
fluorescence spectra before and after exposure to bladder cancer urinary
VOC vapour, the spectrum characteristics: maximum peak value and
wavelength, minimum peak value and wavelength, and peak area were used
for describing the characters of the differential spectrum and to be used as
input for CDA
FIGURE 3 Visible colour changes of sensitive elements on the PVDF film before and after exposure to 1.9 ppm Nonanoyl chloride vapour to demonstrate
the visual changes only, not the composition of the actual sensor array
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As depicted in Figure 3, the visible colour of the sen-
sory film changed after exposure to VOC vapours, and
such changes could be used as sensory responses to the
presence of the VOC. In fact, various first-generation color-
imetric e-nose or artificial tongues were developed based
on this phenomenon [38, 41, 42]. Those devices were com-
posed of chemical responsive material sensory arrays and
scanner or cameras, by taking pictures of the sensory arrays
before and after exposure to test substances, and the colori-
metric changes could be quantized as changes in RGB
value of the picture region. The colorimetric methods have
advantages in cost and ease of use, but the colour changes
sometimes may not be significant enough for RGB differ-
ences calculations, thereby limiting the sensitive material
choices. For example, the sensory point 5 in Figure 3 has
minor visible colour changes (5.b vs. 5.a) when exposed to
VOC vapours but in the near-infrared region, there is a
fluorescence peak intensity changes, meaning that this
material is usable for fluorescence sensors but not colori-
metric sensors. Figure 4 shows the differential spectrum of
fluorescence elements as the responds to the VOCs vapours
under different excitation light. Figure S1A-C showed a
decay in the fluorescence over a week starting 5 minutes
after exposure to VOCs.
FIGURE 4 Sensor point responses to VOCs under excitation by 450-, 532-, and 365-nm laser. The differential spectrum has been denoised using Savitzky-
Golay filtering
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When discussing fluorescence changes, the effect of
water is an unavoidable question, especially when the
humidity of the environment is changing rapidly and unpre-
dictably. Based on this, the substrate and sensitive materials
were carefully selected hydrophobic materials, which can
reduce the effect of water greatly and satisfy the basic
requirement for urine vapour testing. To further verify the
minimal effects of water to the sensitive material, a clean sat-
urated water steam was passed through a fresh prepared sen-
sory film under the room temperature, no detectable
fluorescence shifts, or intensity changes being observed.
Both the VOC biomarker tests and the urine test were carried
out under the room temperature, no further heating was
applied since the testing compounds are all volatility enough
in the room temperature. The pH value of solution will affect
the volatilisation of the VOC molecules; in other way, the
pH value of the urine vapour is also an indicator of human's
FIGURE 5 A, PLS-DA score plot of various concentration test of nonanoyl chloride, vapour concentration: 200 ppt ~ 200 ppb, reaction time: 120 seconds,
carrier gas: nitrogen. B, Differential spectrum of element 1 under 450 nm laser excitation when exposed to various concentration of nonanoyl chloride. C,
Differential spectrum of element 5 under 532-nm laser excitation when exposed to various concentration of nonanoyl chloride
FIGURE 6 CDA score plot of VOCs test, vapour concentration: 1 ppm,
reaction time: 120 seconds, carrier gas: nitrogen
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metabolism activities. The normal level of pH of human
urine is ranged from 5.5 to 8, many studies have found that
low urinary pH has positive correlation to cancer incidence
and recurrence; therefore, we put a fluorescence pH indicator
in our sensory film to include this important factor into anal-
ysis [43–45].
As mentioned previously, the concentrations of VOCs in
human urine vapour are varied from low-ppb to ppt level;
therefore a dedicated test with similar concentration of those
VOC biomarkers is necessary. Four different levels of nona-
noyl chloride vapours were tested with the device and the
results are shown in Figure 5. Figure 5A shows a clear dis-
crimination grouping of 200 ppb, 100 ppb, 5 ppb, and
200 ppt of nonanoyl chloride by PLS-DA, the degree of
sample points dispersion within the group shows that at ppb
level the variation between each measurements is acceptable,
while down to the sub-ppt level the variation becomes bigger
and that also reflected in the spectrum Figure 5B, C, both
elements 1 and 5 have weaker respond to 200 ppt of nona-
noyl chloride; therefore, the PLS-DA has more difficult to
distinguish the signal from the noise, resulting in larger dis-
persion within the 200 ppt group.
FIGURE 7 Example of input dataset for PLS-DA prediction model, the differential spectrum of each sensory point was connected head-to-head and formed
a consequence dataset
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3.2 | Assessments of VOC biomarker detection
For preliminary assessments of VOC biomarker detection,
five spectrum characteristics were extracted from each dif-
ferential spectrum: maximum peak value and wavelength,
minimum peak value and wavelength and peak area. For
each VOC, there are 8 elements × 3 excitation lights × 5 sig-
nal characteristics = 120 characters' value for each single
test. Such character extraction processes can reduce the
dimensions of the data vector as well as the process time for
later discrimination.
As seen in Figure 6, which revealed three discriminant
functions from CDA, the first function explained 96.2% of the
variance, canonical correlation is 0.998, whereas the second
explained 2.1%, canonical correlation is 0.932 and the third
1.7%, canonical correlation is 0.915. In combination, these
discriminant functions significantly differentiated all VOC
groups, the index for describing discrete between groups,
Wilk's Lambda Λ < 0.01, the χ2 test significance under
123 degrees of freedom: χ2 (123) = 233.71, P < 0.01, by
removing the first function indicating that the second and third
functions can still differentiate the four VOC groups but not
significantly, Λ = 0.02, χ2 (80) = 94.07, P = 0.14. The dis-
criminant function plot showed that the first function discrimi-
nated the nonanoyl chloride group from the other groups, and
the second function differentiated the hexanal group from the
remaining two groups and the third function differentiated the
ethylbenzene group from the Laurie aldehyde group.
The biggest advantages of CDA over the frequently used
PCA are that it makes the classification under the pre-set groups,
and it focuses discrimination of the different groups by its dis-
criminant functions rather than similarity within the groups. The
discrimination function, in short, was decided based on the prin-
ciple that keeping the sample variance within the group as small
as possible and maintaining the variance between groups as large
as possible. Such a feature makes it useful in judging the perfor-
mance of the detection methods using known dataset. Success-
fully discriminating VOCs groups by CDA proves the
fluorescence gas-sensor array has the ability to respond to the
presence of different bladder cancer-related VOCs specifically.
3.3 | Prediction model and urine test
PLS-DA has been widely used in building prediction model
in medical applications, and the properties of this discrimina-
tion method made it suitable for small sample sizes, thus it
can reduce the effect of collinearity between variances.
As seen in Figure 7, the fluorescence differential spectra
were employed as input datasets without the need for spec-
trum character extraction. This step kept more signal details
but may also introduce the interference of noise and cause
overfitting. Therefore, leave-one-out cross-validation for all
PLS-DA model training is necessary. As found in Table 2,
the overall sensitivity for VOCs testing was 77.75% with a
specificity of 93.25%. The test passed the leave-one-out
cross-validation by satisfying the condition of both
percentages of explained variances in training (R2) and
cross-validating (Q2) datasets being larger than 0.4. To
increase the accuracy of the prediction model, one straight-
forward method is to increase the number of different sen-
sory elements on the film, by doing that, more specific
responding pattern can be achieved without changing the
main structure of the device.
For the urine tests, all five samples from bladder cancer
patients group were successfully identified using CDA, although
the sample size was not large enough to build the statistically
significant prediction model for PLS-DA, and the positive
response of the fluorescence sensor array to the bladder cancer
patients urine along with the results of VOCs test demonstrated
this method has potential in clinical diagnosis application. Fur-
ther research with larger numbers of participants is in progress
and will be reported subsequently. Other influential factors, such
as smoking, urinary tract infection, and cancer staging, are worth
taking note of and will be included in our future work.
4 | CONCLUSION
In conclusion, we built a novel platform for the detection of
urinary bladder cancer-related urine VOCs, and the experi-
ments have shown that the sensitive material spotting on
PVDF film can respond to the presence of bladder cancer-
related VOCs and to reflect changes in their fluorescence
spectra. Further statistical analysis revealed that the predic-
tion model can reach a high sensitivity (77.75%) and speci-
ficity (93.25%). A comprehensive system was built to
perform the test automatically, through a combination of a
fluorescence sensor array, computer-controlled gas generates
and process system. This was successfully evaluated
employing urinary samples from patients with urinary blad-
der cancer. With suitable statistical tools, the system has the
potential to become a cost-effective point-of-care non-
invasive diagnostic method for urinary bladder cancer.
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TABLE 2 Leave-one-out cross-validation results of the VOCs test prediction
model made by PLS-DA, latent variables = 3, R2 = 0.97,Q2 = 0.83
VOC Test Specificity (%) Sensitivity (%)
Ethylbenzene 12 89 73
Hexanal 12 94 38
Laurie aldehyde 12 90 100
Nonanoyl chloride 12 100 100
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